Feedback / Questions
lirentelimab subcutaneous (AK002 SC) - Allakos
https://www.biospace.com/article/releases/allakos-announces-phase-2-lirentelimab-trials-in-atopic-dermatitis-and-chronic-spontaneous-urticaria-did-not-meet-their-primary-endpoints/
Jan 16, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next